Ian Johnson, Regional Market Access Disease Lead and

Elena Lopatina, Medical Advisor Russia&CIS

Zurich, 01.07.15

Novartis in Uzbekistan

Novartis Group in Uzbekistan

| Presentation Title | Presenter Name | Date | Subject | Business Use Only2

Partnership for life

Presented by Novartis Pharma, Sandoz, Alcon

More than 60 associates employed locally

More than 100 drugs presented at the market

Alcon

Novartis Oncology in Uzbekistan

| Presentation Title | Presenter Name | Date | Subject | Business Use Only3

Aim to improve the quality of life for cancer patients

Every year, we help 1000 patients to enjoy life with their families through the Chronic Myeloid Leucosis (CML) and Thalassemia treatment programs

A few facts about CML

| Presentation Title | Presenter Name | Date | Subject | Business Use Only4

Glivec has converted CML from lethal to chronic disease

Chronic myeloid leukemia (CML) is a life-threatening disease and belongs to a group of blood diseases involving the immune mechanism1

Incidence: 0,6-1 per 100 000 by world data2

Treatment by Glivec (Imatinib) and the next-generation tyrosine inhibitors have dramatically changed the prognosis of these patients and transferred to the rank of "chronic disease" and even potentially curable.3,4

1. Chronic myeloid leukaemia: ESMO CML Clinical Practice Guidelines European Society for Medical Oncology (2010) 2. Rohrbacher M1, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol. 2009 Sep; 22(3):295-302. Mahon FX, et al. Blood 2011;118:abstract 603 4. Rea D, et al. Blood. 2011;118(21):277 [abstract 604].

Novartis Oncology in Uzbekistan

| Presentation Title | Presenter Name | Date | Subject | Business Use Only5

The key highlights of GIPAP in Uzbekistan

1. More than 800 patients enrolled as of 06.20152. Fully donated program by Novartis Oncology, operated by

Max Foundation3. 3,367 CHF is the cost of monthly treatment with Glivec,

Novartis life-saving product for CML patients, provided via GIPAP

Thus, the annual cost of drugs provided by Novartis on free of charge basis would be more than 25.000.000 CHF.

A few facts about Thalassemia

| Presentation Title | Presenter Name | Date | Subject | Business Use Only6

Exjade gives a chance for a long and fool-blooded life for children

Thalassemia is genetic disease that affect the structure of hemoglobin and human blood is not enriched with oxygen. This leads to a serious delay in the psycho-physical development of children with thalassemia. Such patients need lifelong medical and social assistance. 1

Currently in outpatient department of RIHBT* 199 patients with Thalassemia registered. In Uzbekistan annually about 10-15 patients with thalassemia are diagnosed, endemic foci of the disease are in the regions.2

1. Colah R, Gorakshakar A, Nadkarni A. Expert Rev Hematol 2010;3(1);103-117.2. Research Institute of Hematology and blood transfusion MoH (RIHBT), Uzbekistan

Novartis Oncology in Uzbekistan

| Presentation Title | Presenter Name | Date | Subject | Business Use Only7

The key highlights of Thalassemic program

1. More than 200 children patients currently in need for a treatment with iron chelators

2. Government has allocated initial funding to treat children starting from 2015.

3. Novartis is providing a full support to the implementation of the program through educational activities, diagnostics support and infrastructure grants

| Presentation Title | Presenter Name | Date | Subject | Business Use Only8